| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Biotechnology sector is very positive (overall 5, positive 6.7, negative -1.7) on 20251114. The forces of Valuation Sentiment (2.7), Sector Price Trend (1.6), Sentiment towards Fundamentals (1.6), and Option Speculation (0.75) will drive up the price. The forces of Broad Market Trend (-0.2), Price Level (-0.5), and Market Risk Prefrence (-1) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (6.7). The extreme bullish overall sentiment (5) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Market Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | 1% | 0.4% | 164.19 | 96 | 0.53% | 0.31% | 1.6 | 5 | 1.6 | 7.1 |
| 2025-11-13 | 0% | 0.3% | 163.32 | 95 | -0.99% | 0.38% | 1 | 4.9 | 1.7 | 7 |
| 2025-11-12 | 0% | 0.3% | 164.96 | 115 | 0.49% | 0.5% | 2.9 | 6.4 | 1.2 | 5 |
| 2025-11-11 | 1% | 0.4% | 164.15 | 123 | 2.91% | 0.38% | 1.9 | 5.9 | 1.5 | 4.5 |
| 2025-11-10 | 0% | 0.3% | 159.51 | 89 | 1.13% | 0.19% | 0.5 | 5.9 | 1 | 5 |
| 2025-11-09 | 0% | 0.4% | -0.6 | -1.9 | 0.9 | 0 | ||||
| 2025-11-08 | 1% | 0.4% | -0.6 | -2.2 | 0.6 | 6.7 | ||||
| 2025-11-07 | 0% | 0.3% | 157.72 | 71 | -0.45% | 0.13% | -0.6 | -2.1 | 0.7 | 0 |
| 2025-11-06 | 0% | 0.4% | 158.43 | 79 | 0.08% | 0.25% | 0.4 | -1.8 | 0.9 | 8 |
| 2025-11-05 | 1% | 0.4% | 158.31 | 81 | 1.43% | 0.26% | 0.5 | -1.3 | 1.2 | 4.3 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB Behaviors |
| ● Biotechnology (IBB) (-16%) is likely to move marginally lower. When the price move is against the technical setup, sentiment and emotion, it's a sign of trend reversal. |
| 1 (8) Sarepta Shares Jump After FDA Approves Updated Elevidys Label Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys. (https://www.benzinga.com/) Fri. Nov 14, 2025 | |
| 2 (7) New FDA Director Could Sway Biotech ETFs Biotech stocks could sway towards the upside with the appointment of a new director at the FDA's Center for Drug Evaluation and Research. (https://www.etftrends.com/) Fri. Nov 14, 2025 | |
| 3 (8) This Biotech's Stock Price More Than Doubled on Friday. Here's Why. Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment. (https://www.investopedia.com/) Fri. Nov 14, 2025 | |
| 4 (5) This is why Merck is buying a flu biotech for $9.2 billion and Wall Street is happy Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 5 (7) Merck to Buy Cidara Therapeutics in $9.2 Billion Deal Merck Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio. (https://finance.yahoo.com/) Fri. Nov 14, 2025 | |
| 6 (7) Merck agrees $9.2bn deal for flu-prevention biotech Cidara Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming... (https://finance.yahoo.com/) Fri. Nov 14, 2025 | |
| 7 (8) Merck nears deal for flu-prevention biotech Cidara Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting... (https://finance.yahoo.com/) Fri. Nov 14, 2025 | |
| 8 (7) This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday (https://www.benzinga.com/) Thu. Nov 13, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA